甲状腺癌组织LSD1表达临床意义分析  

Expression of LSD1 and its clinical significance in thyroid carcinoma tissues

作　　者：孔灵玲[1] 张国安[1] 崔文[1] 王旭[1] 周建[1] 侯森[1] 张仁亚 

机构地区：[1]济宁医学院基础学院,山东济宁272067 [2]济南医学院附属医院病理科,山东济宁272029

出　　处：《中华肿瘤防治杂志》2013年第2期118-120,共3页Chinese Journal of Cancer Prevention and Treatment

基　　金：山东省自然科学基金(ZR2011HM057);山东省高等学校科技计划(J12K55)

摘　　要：目的:探讨LSD1与甲状腺癌发生发展的关系。方法:免疫组化SP法测定LSD1在甲状腺癌组织中的表达、分布及与临床参数的关系。结果:在甲状腺组织中LSD1阳性表达位于核内。甲状腺癌组织中LSD1的阳性表达率为94.7%,癌旁组织为34.8%,两者比较,U=-5.575,P=0.000;甲状腺腺瘤表达率为73.3%,与癌组织比较,U=-3.190,P=0.001;而甲状腺腺瘤则高于癌旁组织,U=-2.286,P=0.022。LSD1的表达在淋巴结转移组(94.1%)与非淋巴结转移组(95.0%)比较差异无统计学意义,U=-0.364,P=0.716;且LSD1的表达在不同性别、发病年龄及临床分期等方面差异均无统计学意义,P值均>0.05。结论:LSD1是甲状腺肿瘤发生、发展的早期标志,其表达的增加可作为判断甲状腺肿瘤发生及恶性转化的重要临床参考指标。OBJECTIVE:To investigate the prognostic significance of LSD1 expression in patients with thyroid carcinoma.METHODS: The expression of LSD1 in resected samples from thyroid carcinoma patients was detected by immunohistochemistry.RESULTS: LSD1 was localized mainly to the thyroid cell nucleus.Immunohistochemical studies demonstrated that LSD1 expression was higher(94.7%) in thyroid carcinoma than that in thyroid adenoma(73.3%,U=-3.190,P=0.001).LSD1 expression was less frequently in precancerous tissue(34.8%) than that in thyroid carcinoma(U=-5.575,P=0.000) while which in thyroid adenoma was higher than that of precancerous tissues(U=-2.286,P=0.022).There was no difference between cases with positive lymph node metastases(94.1%) and cases with negative lymph nodes(95.0%,U=-0.364,P=0.716).The expression of LSD1 was not significantly associated with gender,age,and stage status(P>0.05).CONCLUSIONS: LSD1 is related with the occurrence and malignant transformation of thyroid carcinoma.The positive expression of LSD1 can be used to estimate the potentiality and help for the adjuvant treatment.

关 键 词：甲状腺肿瘤 LSD1 组蛋白去甲基化酶 免疫组织化学 

分 类 号：R736.1[医药卫生—肿瘤]